Belizatinib (Synonyms: TSR-011) |
| Catalog No.GC19063 |
Le bélizatinib est un inhibiteur oral, double et puissant de l'ALK et du TRKA, du TRKB et du TRKC, avec une IC50 de 0,7nM pour la kinase ALK recombinante de type sauvage.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1357920-84-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
TSR-011 has antitumour activity in the clinical trials.
TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].
References:
[1]. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *